Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial

Durr, Kevin M.; Hendin, Ariel; Perry, Jeffrey J.

doi:10.1007/s43678-022-00293-1

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized, blinded, controlled, and multi-center clinical trial carried out in Europe and India called "COVID STEROID 2", the concentrations of 12 mg (491 patients) and 6 mg (480 patients) of dexamethasone were compared in patients with severe COVID-19 for 10 days. They observed no statistical significance in mortality, serious adverse effects, and the number of days without mechanical ventilation [259].…”

Section: Dexamethasonementioning

confidence: 91%

Severe COVID-19: Drugs and Clinical Trials

Ceja-Gálvez

Renteria-Flores

Nicoletti

et al. 2023

JCM

View full text Add to dashboard Cite

By January of 2023, the COVID-19 pandemic had led to a reported total of 6,700,883 deaths and 662,631,114 cases worldwide. To date, there have been no effective therapies or standardized treatment schemes for this disease; therefore, the search for effective prophylactic and therapeutic strategies is a primary goal that must be addressed. This review aims to provide an analysis of the most efficient and promising therapies and drugs for the prevention and treatment of severe COVID-19, comparing their degree of success, scope, and limitations, with the aim of providing support to health professionals in choosing the best pharmacological approach. An investigation of the most promising and effective treatments against COVID-19 that are currently available was carried out by employing search terms including “Convalescent plasma therapy in COVID-19” or “Viral polymerase inhibitors” and “COVID-19” in the Clinicaltrials.gov and PubMed databases. From the current perspective and with the information available from the various clinical trials assessing the efficacy of different therapeutic options, we conclude that it is necessary to standardize certain variables—such as the viral clearance time, biomarkers associated with severity, hospital stay, requirement of invasive mechanical ventilation, and mortality rate—in order to facilitate verification of the efficacy of such treatments and to better assess the repeatability of the most effective and promising results.

show abstract

Section: Dexamethasonementioning

confidence: 91%

Severe COVID-19: Drugs and Clinical Trials

Ceja-Gálvez

Renteria-Flores

Nicoletti

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

Covid-19 : mise à jour des stratégies thérapeutiques curatives précoces et du patient sous oxygénothérapie

Jaffal,

Davido

2024

Revue des Maladies Respiratoires

View full text Add to dashboard Cite

Rational use of corticosteroid treatment in the early phase of severe COVID-19

Thitayanapong

2023

Clin Crit Care

View full text Add to dashboard Cite

Mechanisms of hypoxemia in COVID-19 pneumonia include pulmonary inflammation, alveolar collapse, atelectasis, and pulmonary intravascular coagulopathy due to a hyperinflammatory response to SARS-CoV-2 infection. Systemic corticosteroids are widely applied as a standard treatment for hospitalized COVID-19 patients after several studies have shown favorable outcomes. However, the standard dosing and tailoring of corticosteroids in COVID-19 patients have not been established. Differences in dosing and timing of corticosteroid use may affect the outcome of COVID-19 patients. Inappropriate use of corticosteroids can lead to less benefit and potentially harmful adverse events. Dexamethasone is the most widely used corticosteroid as a result of the positive outcome from the RECOVERY study and its high anti-inflammatory potency. Although several studies have shown the benefit of higher dose corticosteroids in severe COVID-19 patients, serious adverse events associated with the use of corticosteroids, such as superimposed bacterial and/or fungal infections, have also been observed. Therefore, in this article, we reviewed current evidence of corticosteroid usage in COVID-19 patients and suggested a strategy for tailoring corticosteroid usage according to the clinical severity and risk of the patients.

show abstract

Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial

Cited by 3 publications

References 3 publications

Severe COVID-19: Drugs and Clinical Trials

Severe COVID-19: Drugs and Clinical Trials

Covid-19 : mise à jour des stratégies thérapeutiques curatives précoces et du patient sous oxygénothérapie

Rational use of corticosteroid treatment in the early phase of severe COVID-19

Contact Info

Product

Resources

About